CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists and other healthcare providers involved in the treatment of acute myeloid leukemia (AML).
  
  LEARNING OBJECTIVES

  • Evaluate the importance of age, performance status and other biologic and disease-related factors in the selection and sequencing of therapy for patients with various presentations of AML.
  • Recognize the FDA approval of venetoclax for patients with newly diagnosed AML unfit for intensive therapy, and discern how this agent can be optimally integrated into nonresearch care algorithms.
  • Assess available research evidence with approved and emerging FLT3 inhibitors, and use this information to guide clinical care and protocol opportunities for appropriate patients with newly diagnosed or progressive AML harboring a FLT3 mutation.
  • Develop an understanding of the available data with and current role for available IDH1/2 inhibitors for patients with newly diagnosed or relapsed/refractory AML and an IDH1 or 2 mutation.
  • Design and implement a plan of care to prevent, recognize and manage side effects and toxicities associated with the use of recently approved systemic therapies in the management of AML to support quality of life and continuation of therapy.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Presenting Faculty Member
  
  Eytan M Stein, MD
  Assistant Attending Physician
  Director, Center for Drug Development in Leukemia
  Leukemia Service
  Department of Medicine
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Advisory Committee: Agios Pharmaceuticals Inc, Amgen Inc, Astellas, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Menarini Group, Novartis, PTC Therapeutics, Seattle Genetics, Syros Pharmaceuticals Inc; Contracted Research: Agios Pharmaceuticals Inc, Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Syros Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: Cellectis, Epizyme; Ownership Interest: Auron Therapeutics.
  
  Project Steering Committee Members
  
  Harry P Erba, MD, PhD
  Professor, Department of Medicine
  Director of the Leukemia Program
  Division of Hematologic Malignancies and Cellular Therapy
  Duke Cancer Institute
  Duke University School of Medicine
  Durham, North Carolina
  
  Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, Astellas, Celgene Corporation, Daiichi Sankyo Inc, GlycoMimetics Inc, ImmunoGen Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, MacroGenics Inc, Novartis, Pfizer Inc, Seattle Genetics, Takeda Oncology; Contracted Research: AbbVie Inc, Daiichi Sankyo Inc, ImmunoGen Inc, MacroGenics Inc; Data and Safety Monitoring Board/Committee: GlycoMimetics Inc; Independent Review Committee: AbbVie Inc, Covance; Scientific Steering Committee: Celgene Corporation; Speakers Bureau: Agios Pharmaceuticals Inc, Celgene Corporation, Incyte Corporation, Jazz Pharmaceuticals Inc, Novartis.
  
  Mark Levis, MD, PhD
  Director, Adult Leukemia Program
  Co-Division Director, Hematologic Malignancies
  Professor of Oncology
  The Sidney Kimmel Comprehensive Cancer Center
  Johns Hopkins University
  Baltimore, Maryland
  
  Advisory Committee: Agios Pharmaceuticals Inc, Amgen Inc, Astellas, Daiichi Sankyo Inc, FUJIFILM Pharmaceuticals USA Inc, Menarini Group, Novartis; Contracted Research: Astellas, FUJIFILM Pharmaceuticals USA Inc, Novartis; Data and Safety Monitoring Board/Committee: Astex Pharmaceuticals.
  
  Daniel A Pollyea, MD, MS
  Associate Professor of Medicine
  Clinical Director of Leukemia Services
  Robert H Allen, MD Chair in Hematology Research
  Division of Hematology
  University of Colorado School of Medicine
  Aurora, Colorado
  
  Advisory Committee: AbbVie Inc, Agios Pharmaceuticals Inc, argenx, Celgene Corporation, Celyad, Forty Seven Inc, Gilead Sciences Inc, Janssen Biotech Inc, Pfizer Inc; Consulting Agreements: AbbVie Inc, Astellas, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Takeda Oncology; Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: GlycoMimetics Inc, Tolero Pharmaceuticals.
  
  Keith W Pratz, MD
  Associate Professor of Medicine
  Director of Leukemia Program
  University of Pennsylvania
  Philadelphia, Pennsylvania
  
  Advisory Committee: AbbVie Inc, Agios Pharmaceuticals Inc, Astellas, Boston Biomedical Inc; Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc, Astellas, Takeda Oncology.
  
  Wendy Stock, MD
  Anjuli Seth Nayak Professor of Leukemia Research
  University of Chicago Medicine
  Chicago, Illinois
  
  Advisory Committee: Adaptive Biotechnologies, Agios Pharmaceuticals Inc, Astellas, Daiichi Sankyo Inc, Kite Pharma Inc, Pfizer Inc.
  
  Richard M Stone, MD
  Chief of Staff
  Director, Translational Research, Leukemia Division
  Dana-Farber Cancer Institute
  Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: AbbVie Inc, Amgen Inc, argenx, Arog Pharmaceuticals Inc, Astellas, BioLineRx, Celgene Corporation, Daiichi Sankyo Inc, Novartis, Pfizer Inc, Takeda Oncology, Trovagene; Data and Safety Monitoring Board/Committee: argenx, Celgene Corporation, Takeda Oncology.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AbbVie Inc, Agios Pharmaceuticals Inc and Astellas.
  
  Release date: September 2020
  Expiration date: September 2021